Membership
The Accelerated Access Review is led by an independent chair and supported by the review’s Expert Advisory Group.
Sir Hugh Taylor, Chair
Sir Hugh is Chairman of Guy’s and St Thomas’ NHS Foundation Trust, and a member of the Board of King’s Health Partners, an accredited academic science centre. He was a senior civil servant, working in a variety of senior roles in the NHS Executive, Cabinet Office, Home Office and Department of Health, where he was Permanent Secretary.
Between March and October 2014 he was enlisted as interim chair of Christie Hospital NHS Foundation Trust. He is also Chairman of the National Skills Academy for Health and a trustee of the Nuffield Trust, Macmillan Cancer Support and Cicely Saunders International.
Professor Sir John Bell, Chair of the Review’s Expert Advisory Group
Professor Bell is Regius Professor of Medicine at Oxford University. He was President of the Academy of Medical Sciences from 2006 to 2011. He has been extensively involved in the development of research programmes in genetics and genomics and founded the Wellcome Trust Centre for Human Genetics.
Professor Bell sits on a wide range of advisory panels for public and private sector bodies responsible for biomedical research in Canada, Sweden, Denmark, France, Singapore and the UK. He is also a founding director of three biotechnology start-up companies.
Expert Advisory Group
The EAG comprises leading academics, clinicians, researchers, and those from the medical technology and pharmaceutical industry. The EAG plays a key role in helping to generate recommendations and championing the review among the public and other stakeholders.
Professor Richard Barker
Professor Richard Barker is the director of the Centre for the Advancement of Sustainable Medical Innovation. He chairs the Precision Medicine Catapult and the South London Health Innovation Network and Genomic Medicine Centre. He is a former director general of the Association of the British Pharmaceutical Industry.
Kate Bingham
Kate Bingham is managing partner at SV Life Sciences where she specialises in biotech. She previously worked for Vertex Pharmaceuticals and in consultancy.
Chris Brinsmead CBE
Chris Brinsmead CBE is a non-executive director and chair of a number of public and private companies. He was president of AstraZeneca UK and former president of the Association of the British Pharmaceutical Industry.
Sir John Burn
Sir John Burn is professor of clinical genetics at Newcastle University. He is a non-executive director at NHS England, and chair of DNA diagnostics company QuantuMDx Ltd.
Mike Capaldi
Mike Capaldi is the director of the Edinburgh Bioquarter.
James Champion
James Champion is European Sales Engineering and Program Manager at Qualcomm Life. He was formerly director of strategic accounts at GE Healthcare Limited, and facilitated the establishment of partnerships between global healthcare industry, academic institutes and healthcare organisations.
Dr Stuart Dollow
Dr Stuart Dollow is the founder of, Vermilion Life Sciences. He is a fully GMC registered physician, with senior global pharmaceutical industry leadership experience gained previously at Roche, GlaxoSmithKline, Norgine and Takeda.
Professor Jeremy Farrar
Professor Jeremy Farrar is director of the Wellcome Trust. He has a professional background in global health and infectious diseases.
Professor Sir David Fish
Professor Sir David Fish is managing director at UCLPartners. He was previously medical director of the specialist Hospitals clinical board at UCLH NHS Foundation Trust.
Noel Gordon
Noel Gordon is a non-executive director at NHS England and chair of the specialised commissioning committee. He was previously the global managing director of the banking industry practice at Accenture.
John Jeans
John Jeans is chair of Cardiff University. Previously he was deputy chief executive and chief operating officer at the Medical Research Council. He is former chairman of GE Healthcare Limited.
Alastair Kent
Alastair Kent is chair of the Genetic Alliance, Rare Diseases UK and president of the European Genetic Alliances Network. He is a past chair of the European platform for patient organisations, science and industry.
Jonathan Knowles
Jonathan Knowles is professor in personalised medicine at the University of Helsinki. He is former head of research and member of the executive committee at Roche. He has been on the board at Genentech for the 12 years.
Harpal Kumar
Harpal Kumar is the chief executive of Cancer Research UK and was a healthcare consultant at McKinsey.
Jeremy Levin
Jeremy Levin is the chair of Ovid Therapeutics.
Professor David Lomas
Professor David Lomas is chair of Medicine and Dean of the Faculty of Medical Sciences at University College London. He was previously Professor of Respiratory Biology at the University of Cambridge, and Honorary Consultant Physician at Addenbrooke’s and Papworth hospitals.
Raj Long
Raj Long is a senior regulatory officer at the Bill & Melinda Gates Foundation. She has held roles as vice president at Bristol Myers Squibb and Novartis, and leads the Integrated Development Initiative for Dementia.
Professor Graham Lord
Professor Graham Lord is professor of medicine, King’s College London, honorary consultant nephrologist at Guy’s and St Thomas’ NHS Foundation Trust and director of the NIHR Biomedical Research Centre Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.
Eric Low
Eric Low is the chief executive and founder of Myeloma UK.
Professor Sir Alex Markham
Professor Sir Alex Markham is director of the Molecular Medicine Institute at St James’s University Hospital. He is a non-executive director at Medicines and Healthcare products Regulatory Agency, and was chief executive of Cancer Research UK until 2007.
Keith McNeill
Keith McNeill is the chief executive of Cambridge University Hospitals. Previously the Chief Executive of Metro North Health Service in Brisbane, Keith is an internationally recognised expert in the fields of lung transplantation and pulmonary vascular disease.
Kevin Moore
Kevin Moore is director of Business Therapies. He founded Scotlab and grew it to become one of the most successful life science companies in Scotland.